商品编号


AG-40B-0160-C100



品牌


Adipogen



公司


Adipogen



公司分类


Proteins



Size

100 ?g


商品信息


More Information



Product Details



Synonyms

IL-33 (human) (C208S/C232S Mutant); Interleukin-33 (human) (C208S/C232S Mutant); IL-1F11; NF-HEV



Product Type

Protein



Properties



Source/Host

E. coli



Sequence

Human IL-33 (aa 112-270) is untagged. Amino acids C208 and C232 have been mutated to serine to protect IL-33 from oxidation.



Crossreactivity

Human
Mouse



Specificity

Binds to human and mouse ST2.



BIOLOG
ical Activity

Activates human and mouse ST2-dependent NF-κB pathway.



MW

~17kDa



Purity

≥95% (SDS-PAGE)



Endotoxin Content

<0.01eu mu;g="" purified="" protein="" (lal="" test;="" lonza).="">0.01eu>



Concentration

After reconstitution:
for 10?g size:
0.1mg/ml
for 100?g size:
1mg/ml



Reconstitution

Reconstitute with 100μl sterile water.



Formulation

Lyophilized. Contains PBS.



Other Product Data

UniProt link Q2YEJ5: Interleukin-33 (human)



Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
PBS containing at least 0.1% BSA should be used for further dilutions.



Use/St
ABI
lity

Stable for at least 6 months after receipt when stored at -20°C.



Documents



MSD
S


Download PDF



Product Specification Sheet



Datasheet


Download PDF





Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released upon cell lysis. IL-33 binds to and signals through ST2 (IL-1R1) and its stimulation recruits MYD88, IRAK, IRAK4 and TRAF6, followed by phosphorylation of ERK1 (MAPK3) / ERK2 (MAPK1), p38 (MAPK14) and JNK. The
ABI
lity of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases and sepsis. IL-33 facilitates Treg expansion
in vitro
and
in vivo
. Recently, IL-33 has been involved in
ADI
pocyte differentiation. The
BIOLOG
ical activity of IL-33 at its receptor ST2 is rapidly terminated in the extracellular environment by its oxidation (formation of two disulfide bridges), resulting in an extensive conformational change that disrupts the ST2 binding site. Mutations at amino acids C208S/C232S protect IL-33 from oxidation and increase its activity.


Product References

Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation: E.S. Cohen, et al.; Nat. Commun.
6,
ID8327 (2015)

Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis: S. Trabanelli, et al.; Nat. Commun.
8,
593 (2017)